Lv1
30 积分 2024-11-20 加入
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers
12小时前
待确认
GABAergic circuits drive focal seizures
15天前
已关闭
Pharmacological tools to target NKCC1 in brain disorders
16天前
已完结
2-Aminopyridines as Potent and Selective Nav1.8 Inhibitors Exhibiting Efficacy in a Nonhuman Primate Pain Model
20天前
已完结
An overview of the currently available and emerging long-acting formulations of risperidone for schizophrenia and bipolar disorder
1个月前
已完结
Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease
1个月前
已完结
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
1个月前
已完结
Schizophrenia: from neurochemistry to circuits, symptoms and treatments
2个月前
已完结
Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial
2个月前
已关闭
CNS delivery of targeted protein degraders
2个月前
已完结
皖公网安备34019202002308
